Data and Safety Monitoring Board Approves LyGenesis’s Phase 2a Clinical Trial to Continue and Dose Escalate in Novel Trial of Organ Regeneration
Press Releases
LyGenesis, Inc.  
March 4, 2025

Data and Safety Monitoring Board Approves LyGenesis’s Phase 2a Clinical Trial to Continue and Dose Escalate in Novel Trial of Organ Regeneration

The next four patients will receive a higher dose of LyGenesis's cell therapy to grow functioning liver tissue in patients with end stage liver disease

avatar profile Olean Times Herald

Olean Times Herald


Local & Social